General Counsel Jonathan Miller Raises Concerns Regarding FDA’s Stance on CBD Regulation
WASHINGTON D.C. — On the heels of last week’s U.S. Food and Drug Administration (FDA) webinar for hemp industry stakeholders, “A New Way Forward for Cannabidiol and Other Hemp Products,” U.S. Hemp Roundtable General Counsel, Jonathan Miller, wrote key congressional leaders alerting them of the agency’s misguided use of incomplete safety data as the basis for its continued refusal to regulate CBD as a dietary supplement or food additive.
Miller called out FDA’s reliance on studies, such as one published in April, that use high-dose, pharmaceutical-grade CBD formulations, while ignoring the growing body of evidence demonstrating the safety of CBD at lower amounts, such as those typically found in CBD dietary supplements and foods sold at retail.
Miller called out FDA’s reliance on data and studies, such as those summarized in a review article published in April, that use high-dose, pharmaceutical-grade CBD formulations, while ignoring the growing body of evidence demonstrating the safety of CBD at lower amounts, such as those typically found in CBD dietary supplements and foods sold at retail.
“There are multiple toxicity studies published between 2020 and 2023 demonstrating the safety of CBD at these lower amounts, as well as other studies we expect to be published soon,” Miller notes. “Combined with the low number of adverse events associated with CBD products and real-world, observational data that also points to the safety of CBD, the totality of the evidence paints a much different picture than what is presented by the FDA.”
The full letter, addressed to the chairs and ranking members of the Senate HELP and House Energy & Commerce committees, is available here, and it summarizes and provides links to multiple studies that demonstrate evidence of CBD’s safety.
“There are plenty of beneficial dietary supplements – Vitamin D is a great example – that pose significant safety risks if consumed at high doses,” stated Miller. “As Congress develops plans to ensure the regulation of hemp extracts such as CBD, it should focus its attention on how these products are typically used, and not be distracted by studies that imagine their gross over-consumption which is not a realistic concern.”
The U.S. Hemp Roundtable is the hemp industry’s national advocacy organization, a coalition of dozens of leading companies and organizations committed to safe hemp and CBD products. The Roundtable proudly works in partnership with the industry’s leading national, regional and state grassroots organizations, and is leading the way forward for hemp and CBD products through education and action. More at hempsupporter.com.